Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion
- 20 July 2018
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 44 (5) , 939-949
Abstract
Kappa opioid receptor (KOR) agonists produce analgesic and anti-pruritic effects, but their clinical application was limited by dysphoria and hallucinations. Nalfurafine, a clinically used KOR agonist, does not cause dysphoria or hallucinations at therapeutic doses in humans. We found that in CD-1 mice nalfurafine produced analgesic and anti-scratch effects dose-dependently, like the prototypic KOR agonist U50,488H. In contrast, unlike U50,488H, nalfurafine caused no aversion, anhedonia, or sedation or and a low level of motor incoordination at the effective analgesia and anti-scratch doses. Thus, we established a mouse model that recapitulated important aspects of the clinical observations. We then employed a phosphoproteomics approach to investigate mechanisms underlying differential KOR-mediated effects. A large-scale mass spectrometry (MS)-based analysis on brains revealed that nalfurafine perturbed phosphoproteomes differently from U50,488H in a brain-region specific manner after 30-min treatment. In particular, U50,488H and nalfurafine imparted phosphorylation changes to proteins found in different cellular components or signaling pathways in different brain regions. Notably, we observed that U50,488H, but not nalfurafine, activated the mammalian target of rapamycin (mTOR) pathway in the striatum and cortex. Inhibition of the mTOR pathway by rapamycin abolished U50,488H-induced aversion, without affecting analgesic, anti-scratch, and sedative effects and motor incoordination. The results indicate that the mTOR pathway is involved in KOR agonist-induced aversion. This is the first demonstration that phosphoproteomics can be applied to agonist-specific signaling of G protein-coupled receptors (GPCRs) in mouse brains to unravel pharmacologically important pathways. Furthermore, this is one of the first two reports that the mTOR pathway mediates aversion caused by KOR activation.Keywords
This publication has 65 references indexed in Scilit:
- Construction of human activity‐based phosphorylation networksMolecular Systems Biology, 2013
- Comparative Proteomic Analysis of Eleven Common Cell Lines Reveals Ubiquitous but Varying Expression of Most ProteinsMolecular & Cellular Proteomics, 2012
- Dynamics of the G Protein-coupled Vasopressin V2 Receptor Signaling Network Revealed by Quantitative PhosphoproteomicsMolecular & Cellular Proteomics, 2012
- The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorderProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Selective p38α MAPK Deletion in Serotonergic Neurons Produces Stress Resilience in Models of Depression and AddictionNeuron, 2011
- Global phosphorylation analysis of β-arrestin–mediated signaling downstream of a seven transmembrane receptor (7TMR)Proceedings of the National Academy of Sciences, 2010
- Specification of Neuronal Polarity Regulated by Local Translation of CRMP2 and Tau via the mTOR-p70S6K PathwayJournal of Biological Chemistry, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidationNeurobiology of Learning and Memory, 2008
- Kappa Opioid Receptor Activation of p38 MAPK Is GRK3- and Arrestin-dependent in Neurons and AstrocytesJournal of Biological Chemistry, 2006